Importance-Detailed, nationally-representative data describing high-risk populations and circumstances involved in insulin-related hypoglycemia and errors (IHEs) can inform approaches to individualizing glycemic targets.
(excluding psychiatric and penal institutions) in the U.S. and its territories with a minimum of 6 beds and a 24-hour emergency department (Figure 1). 11 As described elsewhere, 12 trained coders at each hospital review clinical records of every ED visit to identify physician-diagnosed adverse drug events (ADEs), and report up to two medications implicated in the adverse event as well as any concomitant medications documented in the medical record. Coders also record narrative descriptions of the ADE, including preceding events, physician diagnosis, clinical and laboratory testing, treatment administered by emergency medical services (EMS) or ED staff, and discharge disposition.
Denominator Data-We estimated the numbers of U.S. patients who reported having DM and using insulin or oral diabetes agents from the National Health Interview Survey (NHIS), a multistage cluster sample of non-institutionalized civilian households ( Figure 1 ). 13 Institutional Review Board Approval-NEISS-CADES data collection is considered a public health surveillance activity by federal human subjects oversight bodies and does not require human subject review or institutional review board (IRB) approval. 14 NHIS data collection is approved by the IRB at the National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD. No approval is necessary for analyses of deidentified survey data. 15 
DEFINITIONS

ED visits for IHEs included visits to any NEISS-CADES ED from January 1, 2007 through
December 31, 2011 in which there was clinician documentation of (1) insulin-related clinically relevant hypoglycemia (BG <70 mg/dL, diagnosis of "hypoglycemia", or treatment for hypoglycemia), or (2) "insulin overdose" or "insulin reaction", or (3) an error in insulin use (e.g., administration of the wrong insulin dose). ED visits for allergic reactions, local effects (e.g., injection site pain), non-hypoglycemic effects (e.g., "headache" alone) and accidental needlesticks were excluded. Definitions of other variables, including IHE location, clinical presentation, BG levels, hypoglycemia treatments, diabetes therapy, and precipitating factors are provided in eTable 1.
Prevalence of self-reported diabetes from January 1, 2007 through December 31, 2011 was estimated from the number of NHIS respondents who answered "Yes" to the question, "Have you ever been told by a doctor or health professional that you have diabetes or sugar diabetes?". [16] [17] [18] For those ≥ 18 years of age, prevalence of insulin-treated diabetes was estimated via the number of NHIS respondents who answered "Yes" to the question, "Are you now taking insulin?". For those <18 years of age, this question is not asked; thus, prevalence of diagnosed diabetes was used as a proxy for insulin treatment. Insulin-treated patients were considered to be treated with both insulin and oral diabetes agent(s) if they also answered "Yes" to the question, "Are you now taking diabetic pills to lower your blood sugar?".
STATISTICAL ANALYSIS
Each NEISS-CADES record is accompanied by a sample weight based on inverse probability of selection, adjusted for non-response and hospital non-participation, and post-stratified to account for changes in the number of U.S. ED visits each year. Each NHIS record is accompanied by a sample weight based on non-zero probability of selection, with design, ratio, non-response and post-stratification adjustments; post-stratification adjustment is made relative to census control totals for the number of U.S. civilian, non-institutionalized individuals. 19 National estimates and proportions of ED visits and hospitalizations for IHEs and national estimates of patients with diabetes using insulin alone or in combination with oral diabetes agents, with corresponding 95% confidence intervals (CIs) were calculated using the SURVEYMEANS procedure in SAS (version 9.3, SAS Institute, Cary, NC) to account for the sample weights and complex sample designs. Estimates and their corresponding CIs derived from 2007-2011 NEISS-CADES and NHIS data were divided by 5 to obtain average annual estimates and CIs. Estimates based on small numbers of cases (<20) or with a coefficient of variation greater than 30% were considered statistically unstable and are noted in the tables. National estimates were calculated for variables with completed documentation (≥90% of cases); case-based analysis was used for remaining variables.
To estimate rates of ED visits and hospitalizations for IHEs in relation to insulin exposure, we divided (NEISS-CADES-derived) estimates of ED visits or hospitalizations for IHEs by (NHIS-derived) estimates of insulin-treated patients. A similar approach was used to estimate the rates of IHEs by age and sex. Accompanying CIs were calculated accounting for variability in both numerator and denominator estimates, and assuming statistical independence (as these components were derived from separate surveys). 20 These rate estimates were then used to calculate rate ratios (RRs) of ED visits and hospitalizations for IHEs associated with different patient groups. Estimated CIs for RRs were calculated using an initial logarithmic transformation and incorporated the estimated variances of the numerators and denominators of both component rate estimates, which were assumed to be independent across patient populations. 21 (Table 2) .
RESULTS
NUMBERS OF ED VISITS
RATES OF ED VISITS AND HOSPITALIZATIONS
Patients ≥80 years of age had the highest estimated rate of ED visits for IHEs (34.9 per 1,000 insulin-treated patients with diabetes; CI, 20.5-49.3), followed by patients 18-44 years of age (24.3 per 1,000; CI, 15.0-33.6). When all patients ≥65 years of age are considered, the estimated rate was 20.5 per 1000 (CI, 13.2-27.8). Insulin-treated patients ≥80 years of age were more than twice as likely to seek ED evaluation for IHEs than those 65-79 years of age (RR, 2.1; CI, 1.3-3.7) and those 45-64 years of age (RR, 2.5; CI, 1.5-4.3) ( Table 2 ). Patients ≥80 years of age were also almost five times as likely to be hospitalized for IHEs than those 45-64 years of age (RR, 4.9; CI, 2.6.-9.1). No significant differences in the rates of ED visits (RR, 1.0; CI, 0.6-1.6) or hospitalizations (RR, 1.2; CI, 0.6-2.1) for IHEs were identified between female and male patients. Overall, the rate of ED visits for IHEs among patients ≥18 years of age treated with insulin only was five times that of patients treated with insulin and at least one oral diabetes agent (RR, 5.3; CI, 3.2-8.8); the RR decreased as patient age increased ( Table 2) .
SPECIFIC INSULIN AND CONCOMITANT ORAL AGENTS
In an estimated 22.9% of ED visits for IHEs, more than one type of insulin product was documented in the medical record (Table 3) . Long-acting (32.9%) and rapid-acting (26.4%) products were the most commonly-documented insulin product types (eTable 2). Metformin and sulfonylureas were the most commonly-documented concomitant oral diabetes agents, identified in 50.9% (CI, 47.6%-54.2%) and 39.2% (CI, 34.8%-43.6%) of estimated ED visits for IHEs where an oral diabetes agent was documented, respectively.
IHE CHARACTERISTICS -NATIONAL ESTIMATES
Hypoglycemia was documented in an estimated 95.4% of ED visits for IHEs, and severe neurologic sequelae (i.e., hypoglycemia-associated shock, loss of consciousness, or seizure; hypoglycemia-associated injury or fall; or hypoglycemia-associated altered mental status) were documented in an estimated 60.6% (CI, 51.3%-69.9%) of ED visits (Table 3) . Almost one-third (29.3%) of estimated ED visits for IHEs required admission, transfer to another facility, or observation admission; observation admissions comprised 2.1% (CI, 0.9%-3.3%) of estimated ED visits.
IHE CHARACTERISTICS -CASE-BASED ANALYSIS
In most cases (53.3%), IHEs occurred in a home setting (eTable 2). Use of an insulin pump was documented in 6.1% of cases. Over one-half (53.4%) of cases involved a BG level ≤50 mg/dL. Intravenous dextrose 50% was the most common EMS/ED treatment administered (50.8% of cases).
PRECIPITATING FACTORS
Precipitating factors for ED visits for IHEs were documented in an estimated 20.8% (CI, 14.8%-26.9%) of ED visits. When documented, almost one-half (45.9%) involved mealrelated misadventures (e.g., neglecting to eat shortly after taking a rapid-acting insulin, not adjusting insulin regimen in the presence of reduced caloric intake) ( Table 4) . Taking the wrong insulin product was documented in an estimated 22.1% of ED visits for IHEs with documented precipitants, and taking the wrong dose or confusing dosing units was documented in an estimated 12.2% of ED visits with documented precipitants. Among ED visits for IHEs where taking the wrong insulin was documented, the most commonly reported error was mixing up long-acting and rapid-acting insulin products. In an estimated 52.3% (CI, 42.5%-62.0%) of these ED visits, patients reported an intent to take a longacting insulin product (e.g., detemir, glargine), but took a rapid-acting one (e.g., aspart, lispro) instead. The proportion hospitalized did not differ among ED visits where an IHE precipitant was documented (20.7%; CI, 15.9%-25.4%) compared with ED visits without an IHE precipitant documented (31.6%; CI, 22.9%-40.2%).
DISCUSSION
Insulin is an important component of diabetes treatment, but remains complex to manage and poses serious risk of hypoglycemia. 22 These national data quantify the burden and severity of IHEs, identify patient groups at higher risk for these events, and describe precipitating factors that could be targeted by prevention efforts.
Nearly 100,000 ED visits and 30,000 hospitalizations annually for IHEs demonstrate the high frequency and significant health impact of these adverse events. Based on prior cost estimates of ED visits for hypoglycemia, 23 ED visits for IHEs may have cost well over $600 million during the 5-year study period. Direct comparisons of our findings to those of previous studies are limited by differences in study methodologies. One study estimated 40,700 ED visits for insulin and other diabetes agent-related adverse events in 2010 using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for poisoning (962.3) or adverse effects due to insulin or other diabetes agents (E932.3); 24 however, cause-of-injury codes such as these have low sensitivity for identifying many ADEs. 25 Another study estimated that 316,000 visits for hypoglycemia were made to U.S. EDs in 2007 based on reporting of hypoglycemia as the first-listed diagnosis and diabetes as a secondary diagnosis; 26 however, this analysis lacked information on insulin use and could not exclude hypoglycemia episodes related to other factors (e.g., alcohol use, occult infection).
The IHEs we identified were serious events, with BG levels ≤50 mg/dL in over half of cases and severe neurologic manifestations in almost two-thirds of cases. We have previously found insulin to be one of the most commonly implicated drugs in adverse events treated in EDs. 27 Based on the more recent data in this study, IHEs accounted for 1 out of every 8 estimated ED visits for ADEs among the very elderly (≥80 years of age), who sought ED evaluation and were hospitalized for IHEs at rates two and five times higher than those 45-64 years of age, respectively. Other studies have found that Medicare beneficiaries ≥85 years of age are twice as likely to experience a hypoglycemia-related hospitalization compared with those 65-74 years of age, 28 and that re-hospitalizations and mortality are more frequent among older adults (≥66 years of age) with at least one episode of hospitalized hypoglycemia. 29 Although there are notable exceptions, 30-33 until very recently, most diabetes treatment guidelines, quality metrics, and pay-for-performance measures placed little emphasis on hypoglycemia risk factors such as advanced age, limited life expectancy, or frailty. 34 The higher rates of ED visits and hospitalizations for IHEs among older insulin-treated patients with diabetes suggest that individualizing glycemic targets by balancing hypoglycemia risks with long-term benefits of glycemic control is appropriate. 22, [35] [36] [37] Updated guidelines and treatment recommendations are now advising glycemic targets be relaxed for patients with advanced age, high risk of hypoglycemia or shorter life expectancy. 22, 35, 38, 39 For example, the American Geriatrics Society has advocated for avoiding adding medications to achieve tight hemoglobin A 1c control in most adults ≥65 years of age. 40, 41 Tighter glycemic control may continue to be appropriate for functional and cognitively intact elderly patients with diabetes who have longer life expectancy and for whom intensive insulin therapy can be managed safely; 22, 35 however, the high frequency and severity of ED visits for IHEs suggest careful consideration of hypoglycemic sequelae and a cautious approach when deciding whether to start or intensify insulin treatment among older adults, especially the very elderly.
Adoption of a patient-centered approach to setting glycemic targets 9, 10, 42-44 also requires development of healthcare quality metrics which recognize targets based on individual patients' clinical profiles and preferences. 33 Although current National Quality Forumendorsed quality metrics do not yet incorporate variation in A 1c target levels based on hypoglycemia risk, 45, 46 new quality measures might allow for considerations of hypoglycemia risks along with long-term benefits of glycemic control. 47 Enhanced prevention efforts should target commonly-identified IHE precipitants. 48 Although meal-planning is a well-recognized component of diabetes self-management education, 49, 50 the most commonly-documented IHE precipitant in this study was mealrelated misadventure, suggesting further emphasis on meal-planning in diabetes patient education efforts may be needed. Reducing the frequency of missed meals and improving patients' competency in adjusting insulin regimens when food intake is reduced may require both content review (e.g., reviewing patients' understanding of dietetic needs in relation to BG levels) and simulation (e.g., patients demonstrating how they would manage insulin with a missed meal or reduced food intake scenario). 48, 51 Administration of the wrong insulin product (e.g., rapid-acting vs. long-acting agents) was the second most commonly-documented IHE precipitant. The number of U.S. poison control center calls for insulin-related unintentional therapeutic errors increased in the last decade, but the frequency of specific errors, such as using the wrong insulin product, has not been described. 52, 53 Recently, insulin packaging has become more distinguishable; 54 however, mix-ups continue 55 and further product type distinctions (e.g., using packaging color or texture) might be explored for reducing medication errors. Also, diabetes self-management education might emphasize distinguishing insulin types, minimizing mix-ups (e.g., storing rapid-acting and long-acting agents in different locations), and correctly timing insulin administration. 54, 56 This study's findings should be interpreted in the context of the limitations of public health surveillance data. First, these data likely underestimate the total burden of hypoglycemic events as hypoglycemia, although a frequent cause of EMS calls, 57-61 is most often cared for outside of the ED setting. 62 Patients who have hypoglycemia unawareness 63, 64 and whose episodes may not result in EMS or ED care are not counted. Patients who died en route to or in the ED are also not counted. Second, since information on past medical history is limited in the ED medical record, the contributions of risk factors for hypoglycemia such as DM type, intensity and duration of insulin therapy, glycemic control, concomitant medications, and comorbidities were not assessed. Third, the specific insulin brand, formulation, and delivery system were not always documented, which limited the ability to assess differences in ED visits and hospitalizations for IHEs across specific insulin products. Similarly, we did not make detailed comparisons between patients treated with insulin alone and those treated with insulin and oral diabetes agent(s) because documentation of concurrent oral diabetes therapy may have been incomplete. Nonetheless, it is notable that across all adult age groups the rate of estimated ED visits for IHEs was consistently lower among those treated with concurrent oral diabetes therapy, perhaps suggesting concurrent use of long-acting insulin products, with less risk for hypoglycemia. 65 Fourth, BG levels were not specified in approximately one-third of cases; nevertheless, over half of cases still had documented BG ≤50 mg/dL. Other indicators of the seriousness of these events included almost 60,000 estimated ED visits for IHEs with severe neurologic sequelae and almost 30,000 estimated ED visits resulting in hospitalization.
Insulin-related hypoglycemia and errors are clinically significant causes of ED visits and hospitalizations for ADEs, particularly among very elderly patients with diabetes. Reducing ED visits for adverse events related to injectable diabetes agents has been recognized as a national priority for improving the health of Americans in a new Healthy People 2020 goal. 66 Reaching this goal will likely require balancing glycemic risks in vulnerable older patient populations and augmenting prevention efforts targeted at key IHE precipitants, such as meal-related misadventures and insulin product mix-ups. Healthcare quality metrics should evolve based on the most current glycemic control guidelines, and the impact of changing guidelines, quality metrics, and prevention strategies should be evaluated via ongoing national surveillance. 22, 35, [67] [68] [69] 
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. n/a n/a n/a n/a Insulin + oral agent 4 c c n/a n/a n/a n/a ≥18 a Case counts and estimates from the National Electronic Injury Surveillance System -Cooperative Adverse Drug Event Surveillance (NEISS-CADES) project, CDC. Diabetes prevalence estimates from the National Health Interview Survey (NHIS), CDC. "Insulin only" refers to cases where only insulin was documented in the ED medical record and no concomitant oral diabetes agent was documented. "Insulin + oral agent" refers to cases where an oral diabetes agent was documented in addition to insulin in the ED medical record.
b For persons <18 years of age, diabetes therapy is not reported by NHIS; treatment-specific rates were not calculated for this age group ("n/a"). c Estimates based on fewer than 20 cases are not shown. a Case counts and estimates from the National Electronic Injury Surveillance System -Cooperative Adverse Drug Event Surveillance (NEISS-CADES) project, CDC. Refer to eTable 1 for definitions of case characteristics.
b All insulin products reported in the ED medical record, including those implicated in IHEs and those listed as concomitant medications.
c Categories are not mutually exclusive; therefore, percentages may total more than 100%.
d Clinician documentation of error in insulin use (n=323), "insulin overdose" (n=6), or "insulin reaction" (n=11) with no documentation of hypoglycemia.
e Discharge disposition missing for one case.
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